A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer
This study is testing an experimental oral drug called INX-315 to see if it can safely stop or slow down the growth of advanced cancers. It is designed for patients whose cancer has continued to progress even after receiving standard treatments.
This trial is looking for people with advanced breast cancer, ovarian cancer, or other solid tumors that have a specific genetic marker called CCNE1. Participants must have already tried standard treatments that are no longer working for them.
You will receive the study medication, either alone or in combination with other standard cancer therapies like hormone treatments. Doctors will monitor you closely through regular check-ups, blood tests, and medical scans to see how your body reacts to the drug and how the tumor responds.
The study is currently recruiting patients at specific medical centers in Orlando, Florida, and Atlanta and Augusta, Georgia. You should speak with your doctor to see if one of these locations is a good fit for you.
- 1The study drug, INX-315, is an oral pill taken by mouth.
- 2Participation includes receiving either the study drug alone or combined with other approved cancer medications.
- 3Strict safety monitoring is provided throughout the study to ensure your well-being.
- 4This trial is for patients whose cancer has spread and did not respond to or stopped responding to previous therapies.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.